What is Novadiscovery?
Founded in 2010 and headquartered in Lyon, France, Novadiscovery operates at the intersection of health technology and artificial intelligence. The company specializes in conducting in silico clinical trials, a sophisticated simulation process designed to predict the efficacy of new drug candidates and streamline the development pipeline. By leveraging advanced computer modeling, Novadiscovery aims to enhance R&D productivity and improve patient outcomes by providing critical insights ahead of traditional human trials. This innovative methodology positions the company as a key player in the digital health revolution, seeking to de-risk drug development and accelerate the delivery of life-saving therapies.
How much funding has Novadiscovery raised?
Novadiscovery has raised a total of $9.1M across 1 funding round:
Series A
$9.1M
Series A (2021): $9.1M with participation from Debiopharm and Sanofi
Key Investors in Novadiscovery
Debiopharm
Debiopharm is a Swiss biopharmaceutical company focused on the development and commercialization of innovative therapies. The company's investment in Novadiscovery suggests a strategic interest in novel approaches to drug development and clinical trial optimization.
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation. The company focuses on discovering, developing, and delivering medicines and vaccines across immunology, rare diseases, neurology, oncology, and preventive care. Guided by research and patient needs, it works with healthcare partners worldwide to advance sustainable and responsible healthcare solutions.
What's next for Novadiscovery?
The recent major strategic investment signals a new phase of growth and expansion for Novadiscovery. This capital infusion is expected to fuel further development of its in silico trial platform, enhance its market reach, and potentially broaden its therapeutic area focus. As Novadiscovery continues to mature, its strategic objective will likely involve forging deeper partnerships with pharmaceutical giants and contract research organizations, solidifying its position as an indispensable tool in the modern drug discovery and development ecosystem. The company's trajectory suggests a strong emphasis on scaling its operations and further validating its predictive capabilities in real-world clinical settings.
See full Novadiscovery company page
